دورية أكاديمية

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC

التفاصيل البيبلوغرافية
العنوان: Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC
المؤلفون: Drilon, Alexander, Chiu, Chao-Hua, Fan, Yun, Cho, Byoung Chul, Lu, Shun, Ahn, Myung-Ju, Krebs, Matthew G, Liu, Stephen V, John, Thomas, Otterson, Gregory A, Tan, Daniel S W, Patil, Tejas, Dziadziuszko, Rafal, Massarelli, Erminia, Seto, Takashi, Doebele, Robert C, Pitcher, Bethany, Kurtsikidze, Nino, Heinzmann, Sebastian, Siena, Salvatore
المساهمون: A. Drilon, C. Chiu, Y. Fan, B.C. Cho, S. Lu, M. Ahn, M.G. Kreb, S.V. Liu, T. John, G.A. Otterson, D.S.W. Tan, T. Patil, R. Dziadziuszko, E. Massarelli, T. Seto, R.C. Doebele, B. Pitcher, N. Kurtsikidze, S. Heinzmann, S. Siena
سنة النشر: 2022
المجموعة: The University of Milan: Archivio Istituzionale della Ricerca (AIR)
مصطلحات موضوعية: Entrectinib, Intracranial efficacy, NSCLC, ROS1 fusion, Treatment post-crizotinib, Settore MED/06 - Oncologia Medica
الوصف: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion-positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of the median overall survival (OS). An exploratory analysis of entrectinib in ROS1 fusion-positive NSCLC with the central nervous system (CNS)-only progression post-crizotinib is reported.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35663414; volume:3; issue:6; firstpage:1; lastpage:13; numberofpages:13; journal:JTO CLINICAL AND RESEARCH REPORTS; http://hdl.handle.net/2434/930503Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85131050255
DOI: 10.1016/j.jtocrr.2022.100332
الإتاحة: https://doi.org/10.1016/j.jtocrr.2022.100332Test
http://hdl.handle.net/2434/930503Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.EADF1D35
قاعدة البيانات: BASE